» Articles » PMID: 15855327

Functional Defects and the Influence of Age on the Frequency of CD4+ CD25+ T-cells in Type 1 Diabetes

Overview
Journal Diabetes
Specialty Endocrinology
Date 2005 Apr 28
PMID 15855327
Citations 171
Authors
Affiliations
Soon will be listed here.
Abstract

CD4+ CD25+ T-cells appear to play a crucial role in regulating the immune response. Therefore, we evaluated the peripheral blood frequency and function of CD4+ CD25+ T-cells in 70 type 1 diabetic patients and 37 healthy individuals. Interestingly, a positive correlation was observed between increasing age and CD4+ CD25+ T-cell frequency in both subject groups. In contrast to previous studies of nonobese diabetic mice and type 1 diabetic patients, similar frequencies of CD4+ CD25+ and CD4+ CD25(+Bright) T-cells were observed in healthy control subjects and type 1 diabetic patients of similar age. There was no difference between type 1 diabetic subjects of recent-onset versus those with established disease in terms of their CD4+ CD25+ or CD4+ CD25(+Bright) T-cell frequency. However, type 1 diabetic patients were markedly defective in their ability to suppress the proliferation of autologous effector T-cells in vitro. This type 1 diabetes-associated defect in suppression was associated with reduced production of interleukin (IL)-2, gamma-interferon, and transforming growth factor-beta, whereas other cytokines including those of adaptive and innate immunity (IL-10, IL-1beta, IL-6, IL-8, IL-12p70, and tumor necrosis factor-alpha) were similar in control subjects and type 1 diabetic patients. These data suggest that age strongly influences the frequency of CD4+ CD25+ T-cells and that function, rather than frequency, may represent the means by which these cells associate with type 1 diabetes in humans.

Citing Articles

Changes in CD4+CD25HIGH T cells and TGFβ1 levels in different stages of adult-onset type 1 diabetes.

Milicic T, Jotic A, Markovic I, Popadic D, Lalic K, Uskokovic V J Med Biochem. 2025; 43(6):915-926.

PMID: 39876913 PMC: 11771973. DOI: 10.5937/jomb0-49868.


The Increased Frequency of Type 1 Regulatory T (Tr1) Cells and the Altered Expression of Aryl Hydrocarbon Receptor (AHR) and Interferon Regulatory Factor-4 (IRF4) Genes in Type 1 Diabetes: A Case-Control Study.

Sameir M, Soleimanifar N, Assadiasl S, Selman N, Sadr M, Mojtahedi H Cureus. 2024; 16(7):e65749.

PMID: 39211721 PMC: 11361286. DOI: 10.7759/cureus.65749.


Regulatory T Cell Dysfunction in Autoimmune Diseases.

Honing D, Luiten R, Matos T Int J Mol Sci. 2024; 25(13).

PMID: 39000278 PMC: 11241405. DOI: 10.3390/ijms25137171.


Translational kinetic-pharmacodynamics of mRNA-6231, an investigational mRNA therapeutic encoding mutein interleukin-2.

Rajlic I, Guglieri-Lopez B, Rangoonwala N, Ivaturi V, Van L, Mori S CPT Pharmacometrics Syst Pharmacol. 2024; 13(6):1067-1078.

PMID: 38676306 PMC: 11179705. DOI: 10.1002/psp4.13142.


Improving regulatory T cell production through mechanosensing.

Shi L, Lim J, Kam L J Biomed Mater Res A. 2024; 112(7):1138-1148.

PMID: 38450935 PMC: 11065567. DOI: 10.1002/jbm.a.37702.